Collegium to Participate in Upcoming Investor Conferences
Collegium Pharmaceutical (Nasdaq: COLL) has announced its upcoming participation in three major healthcare investor conferences in March 2025. The company's management will engage in investor meetings at the Leerink Partners 2025 Global Healthcare Conference on March 11, the Jefferies Biotech on the Beach Summit on March 12, and the Barclays 27th Annual Global Healthcare Conference on March 13.
Collegium Pharmaceutical (Nasdaq: COLL) ha annunciato la sua partecipazione a tre importanti conferenze per investitori nel settore sanitario a marzo 2025. La direzione dell'azienda parteciperà a incontri con gli investitori durante il Leerink Partners 2025 Global Healthcare Conference l'11 marzo, il Jefferies Biotech on the Beach Summit il 12 marzo, e il Barclays 27th Annual Global Healthcare Conference il 13 marzo.
Collegium Pharmaceutical (Nasdaq: COLL) ha anunciado su próxima participación en tres importantes conferencias de inversores en el sector salud en marzo de 2025. La dirección de la empresa se reunirá con inversores en la Leerink Partners 2025 Global Healthcare Conference el 11 de marzo, en el Jefferies Biotech on the Beach Summit el 12 de marzo, y en la Barclays 27th Annual Global Healthcare Conference el 13 de marzo.
콜레기움 제약 (Nasdaq: COLL)는 2025년 3월에 열리는 세 가지 주요 헬스케어 투자자 회의에 참석할 예정이라고 발표했습니다. 회사 경영진은 3월 11일 리링크 파트너스 2025 글로벌 헬스케어 컨퍼런스, 3월 12일 제퍼리스 바이오텍 온 더 비치 서밋, 3월 13일 바클레이스 제27회 연례 글로벌 헬스케어 컨퍼런스에서 투자자 회의에 참여할 것입니다.
Collegium Pharmaceutical (Nasdaq: COLL) a annoncé sa prochaine participation à trois grandes conférences d'investisseurs dans le secteur de la santé en mars 2025. La direction de l'entreprise participera à des réunions d'investisseurs lors de la Leerink Partners 2025 Global Healthcare Conference le 11 mars, du Jefferies Biotech on the Beach Summit le 12 mars, et de la Barclays 27th Annual Global Healthcare Conference le 13 mars.
Collegium Pharmaceutical (Nasdaq: COLL) hat seine bevorstehende Teilnahme an drei wichtigen Investorenkonferenzen im Gesundheitswesen im März 2025 angekündigt. Das Management des Unternehmens wird an Investorenmeetings während der Leerink Partners 2025 Global Healthcare Conference am 11. März, dem Jefferies Biotech on the Beach Summit am 12. März und der Barclays 27th Annual Global Healthcare Conference am 13. März teilnehmen.
- None.
- None.
STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in investor meetings at the following investor conferences:
Leerink Partners 2025 Global Healthcare Conference
Tuesday, March 11, 2025
Jefferies Biotech on the Beach Summit
Wednesday, March 12, 2025
Barclays 27th Annual Global Healthcare Conference
Thursday, March 13, 2025
About Collegium Pharmaceutical, Inc.
Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM®, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.
Investor Contacts:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com
Danielle Jesse
Director, Investor Relations
ir@collegiumpharma.com
Media Contact:
Cheryl Wheeler
Head of Corporate Communications
communications@collegiumpharma.com
FAQ
Which investor conferences will Collegium Pharmaceutical (COLL) attend in March 2025?
When is Collegium Pharmaceutical (COLL) presenting at the Leerink Partners 2025 Conference?
What is the schedule for COLL's participation in the Barclays Healthcare Conference 2025?
Is Collegium (COLL) participating in the Jefferies Biotech on the Beach Summit 2025?
